|Articles|January 11, 2023
- Pharmaceutical Executive: January 2023
- Volume 43
- Issue 01
What We Foresee in ’23: Pharm Exec’s Annual Industry Outlook
Exploring the most relevant topics affecting the biopharma industry as the new year gets underway—ranging from trends ripe with risk and opportunity to those driving more definitive growth opportunities in patient care.
Advertisement
Articles in this issue
almost 3 years ago
Key Factors Attributing to a Successful Product Launchalmost 3 years ago
Closing the Digital Gap: FDA’s Oversight of Social Mediaalmost 3 years ago
Sales-Rep Compensation: Adding Long-Term Incentives to Mixalmost 3 years ago
Co-creating New Innovationsalmost 3 years ago
The Potential Impact of the IRAalmost 3 years ago
Patient Hubs Continue Growthalmost 3 years ago
Social Media’s Complex Climbalmost 3 years ago
Industry Workforce Seeks Clarityalmost 3 years ago
Cybersecurity Threats & PharmaNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly’s and Novo’s Stocks React to President Trump’s Comments on GLP-1 Prices
2
All of the Medications Announced as Part of FDA’s National Priority Voucher Program
3
Autonomous Omnichannel: When AI Thinks for Pharma Marketing
4
EMD Serono Announces Agreement with Trump Administration Increasing Access to In Vitro Fertilization Therapies for US Patients
5
